Skip to content

The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: a Survey Based Experiment

Karla Hitchins, James P. Reynolds

International Journal of Drug Policy August 1, 2025 DOI: 10.1016/j.drugpo.2025.104909 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 804
Population Online participants
Interventions evidence for psilocybin benefits evidence for psilocybin safety
Topics Psilocybin
Keywords Survey research Hallucinogen
Citations 1
Key findings Providing evidence about the benefits and safety of psilocybin increases public support for psilocybin policies and strengthens beliefs about psilocybin.

Abstract

Background: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently illegal in the UK. Less is known about how people form their attitudes towards psilocybin policies.

Objectives: To explore whether beliefs about the benefits and safety of psilocybin influence support for psilocybin policies.

Methods: In an online survey experiment, 804 participants were randomised to receive one of four interventions in a 2 (no information vs evidence for psilocybin benefits) x 2 (no information vs evidence for psilocybin safety) design. Public support for four psilocybin policies and beliefs about the benefits and safety of psilocybin were measured before and after participants were randomised to a group.

Results: In a two-way ANCOVA, the Benefits Intervention significantly increased policy support overall (d = 0.11, p < .001); and for two of four psilocybin policies when analysed separately. Furthermore, the Benefits Intervention significantly strengthened beliefs that psilocybin is beneficial (d = 0.44, p < .001) and safe (d = 0.26, p < .001). The Safety Intervention increased psilocybin policy support overall (d = 0.10, p = .003); and for three of four psilocybin policies when analysed separately. The Safety Intervention also strengthened beliefs that psilocybin is safe (d = 0.28, p < .001) but not that it is beneficial.

Conclusions: Communicating the benefits and safety of psilocybin can increase psilocybin policy support and strengthen beliefs about psilocybin, however further research is needed to explore the longevity of these results.

Comparable studies

Other randomized controlled trials on psilocybin, most cited first.

Study Year Design Participants
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Trial of Psilocybin versus Escitalopram for Depression Selected group of patients with depression 2021 Randomized controlled trial
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Adults aged 21 to 75 years with major depressive disorder, not currently using... 2020 Randomized controlled trial n = 24

Citations in the library

Explore topics